Category: Biotech

MSD for Mothers Commits $10 Million and Business Expertise to the…

MSD for Mothers Commits $10 Million and Business Expertise to the Global Financing Facility to Help End Preventable Deaths of Mothers MSD, known as Merck & Co., Inc., Kenilworth, N.J., U.S.A., inside the United States and Canada, announced today its $10 million commitment to the Global Financing Facility in support of Every Woman Every Child to improve maternal and child health in low- and lower-middle-income countries worldwide through its MSD for Mothers initiative.

This Dividend Anchor Could Return More Than 23% In 2017

Pfizer has been on a roll lately, recently announcing successful top-line results for its third biosimilar in the last four months. The success of its biosimilar initiatives could potentially give Pfizer a secure foothold in the biosimilars market, which could grow to $20 billion in just three years.

For Merck, Keytruda Is ‘Extraordinarily Positive’ : More Squawk From Jim Cramer

Merck’s lung cancer treatment will get a speedy review by the FDA, but it ‘knows better than to go out and give false hope,’ TheStreet’s Jim Cramer said. Shares of Merck were higher in late morning trading Wednesday, after the company announced the U.S. Food and Drug Administration would make a decision by May 10 on its lung cancer treatment that combines the immune system-boosting drug Keytruda with chemotherapy.

Amgen updates agreement with DaVita for dialysis treatment

Thousand Oaks biotech company Amgen entered into a six-year supply agreement with DaVita for dialysis treatments, the company announced on Jan. 9. Under the terms of the new agreement, Amgen will supply DaVita with Epogen and Aranesp for agents to stimulate red blood cells in dialysis treatment in the United States and Puerto Rico.

BioCryst Receives Health Canada Approval for RAPIVAB for the Treatment of Influenza

RESEARCH TRIANGLE PARK, N.C., Jan. 08, 2017 — BioCryst Pharmaceuticals, Inc. , a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced that Health Canada has approved RAPIVAB i 1 2 , an intravenous treatment for acute, uncomplicated influenza.i 1 2 RAPIVAB is approved by the U.S. Food & Drug Administration and is also licensed for use in Japan and Taiwan as RAPIACTAi 1 2 and in Korea as PeramiFlui 1 2.i 1 2 i 1 2This RAPIVAB approval represents an important milestone for BioCryst and for our partner, Seqirus,i 1 2 said Jon P. Stonehouse, President & Chief Executive Officer .i 1 2 i 1 2We are excited that patients in Canada will soon have an I.V. option for the treatment of influenza infections.i 1 2i 1 2 RAPIVAB is being commercialized by Seqirus globally, excluding Japan, Taiwan, Korea and Israel.i 1 2 Seqirus is a … (more)

Better Buy: Regeneron Pharmaceuticals, Inc. vs. Pfizer

Sales of Regeneron’s lead product have been tapering off, but a handful of potential blockbusters could provide some big gains in 2017 and beyond. The pharma giant, meanwhile, also has some exciting growth drivers in its lineup, but an aging product line will make big gains difficult going forward.

Forget Gilead Sciences Inc.: These 2 Stocks Doubled Last Year

Despite a generally bleak year for Gilead, and for biotech stocks in general, shares of Exelixis, Inc. Can these biotechs continue climbing throughout the new year and beyond, or are they about to sputter and run out of fuel? Let’s look at what’s propelling them upward to see why they might be better picks than Gilead Sciences. A string of good news for Exelixis’ lead cancer drug made this one of the best-performing biotech stocks of 2016.

Better Buy: Alnylam Pharmaceuticals vs. Ionis Pharmaceuticals

Treating diseases that have a genetic component by altering the expression of the responsible genes is a promising new field of medicine, but it has been much less straightforward than biopharmaceutical companies had expected. Two contenders in this area, Alnylam Pharmaceuticals In 2016, these two stocks have taken paths as varied as their approaches to drug development, and the past few months have been a wild ride.

article

… and Opko’s longer-lasting candidate might have performed even better with a more convenient dosing schedule. Opko Health isn’t throwing in the towel just yet. Although hGH-CTP failed to significantly reduce trunk fat mass compared to a placebo after …

Number of shares and votes in Active Biotech

Today, the last trading day of the month, there are in total 96,824,320 shares and votes in Active Biotech. For further information, please contact: Tomas Leanderson, CEO Tel: +46 46 19 20 95 E-mail: tomas.leanderson@activebiotech.com Active Biotech AB is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer.